Definition

A preparation of T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) C-type lectin domain family 12 member A (CLEC12A, CCL1, CD371), and expressing the pro-inflammatory cytokine interleukin 18 (IL-18), with potential antineoplastic activity. Upon intravenous administration, CD371-specific/YSNVz/IL-18 CAR T cells target, bind to, and induce selective toxicity in CD371-expressing tumor cells. IL-18 promotes T-cell persistence and potentiates the immune response against tumor cells. CD371 is expressed on the surface of acute myeloid leukemia (AML) cells and leukemic stem cells, but it is not expressed on normal hematopoietic stem cells (HSCs).